The association between hospital variation in curative treatment for esophagogastric cancer and health-related quality of life and survival

Pauline A.J. Vissers; Josianne C.H.B.M. Luijten; Valery E.P.P. Lemmens; Hanneke W.M. van Laarhoven; Marije Slingerland; Bas P.L. Wijnhoven; C. Rosman; Stella Mook; Joos Heisterkamp; Ellen M. Hendriksen; Suzanne S. Gisbertz; Grard A.P. Nieuwenhuijzen; Rob H.A. Verhoeven

doi:10.1016/j.ejso.2023.107019

The association between hospital variation in curative treatment for esophagogastric cancer and health-related quality of life and survival

Pauline A.J. Vissers^*, Josianne C.H.B.M. Luijten, Valery E.P.P. Lemmens, Hanneke W.M. van Laarhoven, Marije Slingerland, Bas P.L. Wijnhoven, C. Rosman, Stella Mook, Joos Heisterkamp, Ellen M. Hendriksen, Suzanne S. Gisbertz, Grard A.P. Nieuwenhuijzen, Rob H.A. Verhoeven

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

45 Downloads (Pure)

Abstract

Background:

As previous studies showed significant hospital variation in curative treatment of esophagogastric cancer, this study assesses the association between this variation and overall, cancer-specific and recurrence-free survival, and Health-Related Quality of Life (HRQoL).

Methods:

Patients diagnosed with potentially curable esophageal or gastric cancer between 2015 and 2018 as registered in the Netherlands Cancer Registry were included. Data on overall survival was available for all patients, data on cancer-specific and recurrence-free survival and HRQoL was available for subgroups. Patients were classified according to diagnosis in hospitals with low, medium or high probability of treatment with curative intent (LP, MP or HP). Multivariable models were used to assess the association between LP, MP and HP hospitals and HRQoL and survival.

Results:

This study includes 7,199 patients with esophageal, and 2,407 with gastric cancer. Overall and cancer-specific survival was better for patients diagnosed in HP versus LP hospitals for both esophageal (HR = 0.82, 95%CI:0.77–0.88 and HR = 0.82, 95%CI:0.75–0.91, respectively), and gastric cancer (HR = 0.82, 95%CI:0.73–0.92 and HR = 0.74, 95%CI:0.64–0.87, respectively). These differences disappeared after adjustments for treatment. Recurrence-free survival was worse for gastric cancer patients diagnosed in HP hospitals (HR = 1.50, 95%CI:1.14–1.96), which disappeared after adjustment for radicality of surgery. Minor, but no clinically relevant, differences in HRQoL were observed.

Conclusions:

Patients diagnosed in hospitals with a high probability of treatment with curative intent have a better overall and cancer-specific but not recurrence-free survival, while minor differences in HRQoL were observed.

Original language	English
Article number	107019
Journal	European Journal of Surgical Oncology
Volume	49
Issue number	10
DOIs	https://doi.org/10.1016/j.ejso.2023.107019
Publication status	Published - Oct 2023

Bibliographical note

Funding Information:
This study was funded by a grant from the Dutch Cancer Society (project number 10895 ). Data on recurrence-free survival was collected within a separate project that was funded by Bristol Myers Squibb ( CA209-77E ). The data collection for the Prospective Observational Cohort Study of Esophageal-gastric cancer Patients (POCOP) was funded by the Dutch Cancer Society (project number UVA 2014–7000 ). The funders had no role in study design, data collection and analysis, preperation of the mancuscript or decision to publish.

Publisher Copyright:
© 2023 The Authors

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ejso.2023.107019Licence: CC BY

The association between hospital variation in curative treatment for esophagogastric cancer and health-related quality of life and survivalFinal published version, 4.98 MBLicence: CC BY

Cite this

Vissers, P. A. J., Luijten, J. C. H. B. M., Lemmens, V. E. P. P., van Laarhoven, H. W. M., Slingerland, M., Wijnhoven, B. P. L., Rosman, C., Mook, S., Heisterkamp, J., Hendriksen, E. M., Gisbertz, S. S., Nieuwenhuijzen, G. A. P., & Verhoeven, R. H. A. (2023). The association between hospital variation in curative treatment for esophagogastric cancer and health-related quality of life and survival. European Journal of Surgical Oncology, 49(10), Article 107019. https://doi.org/10.1016/j.ejso.2023.107019

@article{e8f4e0efb69448efaa5283b557d8d7ed,

title = "The association between hospital variation in curative treatment for esophagogastric cancer and health-related quality of life and survival",

abstract = "Background: As previous studies showed significant hospital variation in curative treatment of esophagogastric cancer, this study assesses the association between this variation and overall, cancer-specific and recurrence-free survival, and Health-Related Quality of Life (HRQoL). Methods: Patients diagnosed with potentially curable esophageal or gastric cancer between 2015 and 2018 as registered in the Netherlands Cancer Registry were included. Data on overall survival was available for all patients, data on cancer-specific and recurrence-free survival and HRQoL was available for subgroups. Patients were classified according to diagnosis in hospitals with low, medium or high probability of treatment with curative intent (LP, MP or HP). Multivariable models were used to assess the association between LP, MP and HP hospitals and HRQoL and survival. Results: This study includes 7,199 patients with esophageal, and 2,407 with gastric cancer. Overall and cancer-specific survival was better for patients diagnosed in HP versus LP hospitals for both esophageal (HR = 0.82, 95%CI:0.77–0.88 and HR = 0.82, 95%CI:0.75–0.91, respectively), and gastric cancer (HR = 0.82, 95%CI:0.73–0.92 and HR = 0.74, 95%CI:0.64–0.87, respectively). These differences disappeared after adjustments for treatment. Recurrence-free survival was worse for gastric cancer patients diagnosed in HP hospitals (HR = 1.50, 95%CI:1.14–1.96), which disappeared after adjustment for radicality of surgery. Minor, but no clinically relevant, differences in HRQoL were observed.Conclusions: Patients diagnosed in hospitals with a high probability of treatment with curative intent have a better overall and cancer-specific but not recurrence-free survival, while minor differences in HRQoL were observed.",

author = "Vissers, {Pauline A.J.} and Luijten, {Josianne C.H.B.M.} and Lemmens, {Valery E.P.P.} and {van Laarhoven}, {Hanneke W.M.} and Marije Slingerland and Wijnhoven, {Bas P.L.} and C. Rosman and Stella Mook and Joos Heisterkamp and Hendriksen, {Ellen M.} and Gisbertz, {Suzanne S.} and Nieuwenhuijzen, {Grard A.P.} and Verhoeven, {Rob H.A.}",

note = "Funding Information: This study was funded by a grant from the Dutch Cancer Society (project number 10895 ). Data on recurrence-free survival was collected within a separate project that was funded by Bristol Myers Squibb ( CA209-77E ). The data collection for the Prospective Observational Cohort Study of Esophageal-gastric cancer Patients (POCOP) was funded by the Dutch Cancer Society (project number UVA 2014–7000 ). The funders had no role in study design, data collection and analysis, preperation of the mancuscript or decision to publish. Publisher Copyright: {\textcopyright} 2023 The Authors",

year = "2023",

month = oct,

doi = "10.1016/j.ejso.2023.107019",

language = "English",

volume = "49",

journal = "European Journal of Surgical Oncology",

issn = "0748-7983",

number = "10",

}

Vissers, PAJ, Luijten, JCHBM, Lemmens, VEPP, van Laarhoven, HWM, Slingerland, M, Wijnhoven, BPL, Rosman, C, Mook, S, Heisterkamp, J, Hendriksen, EM, Gisbertz, SS, Nieuwenhuijzen, GAP & Verhoeven, RHA 2023, 'The association between hospital variation in curative treatment for esophagogastric cancer and health-related quality of life and survival', European Journal of Surgical Oncology, vol. 49, no. 10, 107019. https://doi.org/10.1016/j.ejso.2023.107019

The association between hospital variation in curative treatment for esophagogastric cancer and health-related quality of life and survival. / Vissers, Pauline A.J.; Luijten, Josianne C.H.B.M.; Lemmens, Valery E.P.P. et al.
In: European Journal of Surgical Oncology, Vol. 49, No. 10, 107019, 10.2023.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - The association between hospital variation in curative treatment for esophagogastric cancer and health-related quality of life and survival

AU - Vissers, Pauline A.J.

AU - Luijten, Josianne C.H.B.M.

AU - Lemmens, Valery E.P.P.

AU - van Laarhoven, Hanneke W.M.

AU - Slingerland, Marije

AU - Wijnhoven, Bas P.L.

AU - Rosman, C.

AU - Mook, Stella

AU - Heisterkamp, Joos

AU - Hendriksen, Ellen M.

AU - Gisbertz, Suzanne S.

AU - Nieuwenhuijzen, Grard A.P.

AU - Verhoeven, Rob H.A.

N1 - Funding Information: This study was funded by a grant from the Dutch Cancer Society (project number 10895 ). Data on recurrence-free survival was collected within a separate project that was funded by Bristol Myers Squibb ( CA209-77E ). The data collection for the Prospective Observational Cohort Study of Esophageal-gastric cancer Patients (POCOP) was funded by the Dutch Cancer Society (project number UVA 2014–7000 ). The funders had no role in study design, data collection and analysis, preperation of the mancuscript or decision to publish. Publisher Copyright: © 2023 The Authors

PY - 2023/10

Y1 - 2023/10

N2 - Background: As previous studies showed significant hospital variation in curative treatment of esophagogastric cancer, this study assesses the association between this variation and overall, cancer-specific and recurrence-free survival, and Health-Related Quality of Life (HRQoL). Methods: Patients diagnosed with potentially curable esophageal or gastric cancer between 2015 and 2018 as registered in the Netherlands Cancer Registry were included. Data on overall survival was available for all patients, data on cancer-specific and recurrence-free survival and HRQoL was available for subgroups. Patients were classified according to diagnosis in hospitals with low, medium or high probability of treatment with curative intent (LP, MP or HP). Multivariable models were used to assess the association between LP, MP and HP hospitals and HRQoL and survival. Results: This study includes 7,199 patients with esophageal, and 2,407 with gastric cancer. Overall and cancer-specific survival was better for patients diagnosed in HP versus LP hospitals for both esophageal (HR = 0.82, 95%CI:0.77–0.88 and HR = 0.82, 95%CI:0.75–0.91, respectively), and gastric cancer (HR = 0.82, 95%CI:0.73–0.92 and HR = 0.74, 95%CI:0.64–0.87, respectively). These differences disappeared after adjustments for treatment. Recurrence-free survival was worse for gastric cancer patients diagnosed in HP hospitals (HR = 1.50, 95%CI:1.14–1.96), which disappeared after adjustment for radicality of surgery. Minor, but no clinically relevant, differences in HRQoL were observed.Conclusions: Patients diagnosed in hospitals with a high probability of treatment with curative intent have a better overall and cancer-specific but not recurrence-free survival, while minor differences in HRQoL were observed.

AB - Background: As previous studies showed significant hospital variation in curative treatment of esophagogastric cancer, this study assesses the association between this variation and overall, cancer-specific and recurrence-free survival, and Health-Related Quality of Life (HRQoL). Methods: Patients diagnosed with potentially curable esophageal or gastric cancer between 2015 and 2018 as registered in the Netherlands Cancer Registry were included. Data on overall survival was available for all patients, data on cancer-specific and recurrence-free survival and HRQoL was available for subgroups. Patients were classified according to diagnosis in hospitals with low, medium or high probability of treatment with curative intent (LP, MP or HP). Multivariable models were used to assess the association between LP, MP and HP hospitals and HRQoL and survival. Results: This study includes 7,199 patients with esophageal, and 2,407 with gastric cancer. Overall and cancer-specific survival was better for patients diagnosed in HP versus LP hospitals for both esophageal (HR = 0.82, 95%CI:0.77–0.88 and HR = 0.82, 95%CI:0.75–0.91, respectively), and gastric cancer (HR = 0.82, 95%CI:0.73–0.92 and HR = 0.74, 95%CI:0.64–0.87, respectively). These differences disappeared after adjustments for treatment. Recurrence-free survival was worse for gastric cancer patients diagnosed in HP hospitals (HR = 1.50, 95%CI:1.14–1.96), which disappeared after adjustment for radicality of surgery. Minor, but no clinically relevant, differences in HRQoL were observed.Conclusions: Patients diagnosed in hospitals with a high probability of treatment with curative intent have a better overall and cancer-specific but not recurrence-free survival, while minor differences in HRQoL were observed.

UR - http://www.scopus.com/inward/record.url?scp=85169031150&partnerID=8YFLogxK

U2 - 10.1016/j.ejso.2023.107019

DO - 10.1016/j.ejso.2023.107019

M3 - Article

C2 - 37659340

AN - SCOPUS:85169031150

SN - 0748-7983

VL - 49

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

IS - 10

M1 - 107019

ER -

The association between hospital variation in curative treatment for esophagogastric cancer and health-related quality of life and survival

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this